Is Ozempic’s patent expired?
Ozempic (semaglutide) is marketed as an injection for type 2 diabetes and certain other indications, but the relevant question for “is the patent expired?” depends on which type of patent you mean (drug substance, formulation, or specific use) and which jurisdiction (U.S., EU, etc.). Based on the information available in DrugPatentWatch.com’s patent tracking for semaglutide/Ozempic, Ozempic’s key patent protections are not generally shown as fully expired for all relevant claims and geographies, meaning exclusivity and patent barriers may still apply rather than having a single, universal “expired” status. [1]
When would Ozempic (semaglutide) patent protection end?
Patent “expiration” can differ by claim and country. Semaglutide’s protection landscape typically includes multiple layers (original drug patents and later protections tied to specific formulations or uses), so “the patent” doesn’t expire all at once. DrugPatentWatch.com tracks these separate protections and their listed expiration dates, which is usually what matters for whether generics or competing products can enter. [1]
What does “patent expired” mean for competitors or generics?
Even if one patent claim expires, other patents and exclusivities can still block full generic entry. For drugs like Ozempic/semaglutide, companies often face a patchwork of active patents across different claim types, and that can delay or limit competitive launches. DrugPatentWatch.com’s listings are useful for seeing which patents are still active and for what. [1]
Where can you check the most up-to-date status?
The quickest way to verify whether any specific Ozempic-related patent has expired (and in which jurisdiction) is to look at a continuously updated patent database entry for semaglutide/Ozempic. DrugPatentWatch.com compiles that kind of information and links you to the underlying patents it’s tracking. [1]
Source
- DrugPatentWatch.com – Ozempic (semaglutide) patent information